INCY vs UTHR vs GMAB
161 measures in 16 categories, one definition each, computed from filings and market data.
UTHR73.1
United Therapeutics Corporation
Healthcare · Biotechnology
$533.12 −1.55%$22.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
INCY UTHR GMAB · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 0 | 0 |
| Last Congress purchase | 2026-09-04 | — | — |
| 13F net change in holders | +45 | +36 | +19 |
| ETFs adding shares, 30d | 1,118 | 766 | 34 |
| ETFs trimming, 30d | 852 | 678 | 22 |
| Net ETF funds, 30d | +266 | +88 | +12 |
Valuation
16 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| P/E (TTM) | 14.2x
35th
|
17.4x
43rd
|
28.9x
62nd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.21
11th
|
0.99
67th
|
— |
| Price / sales | 3.9x
21st
|
7.2x
42nd
|
5.5x
31st
|
| Price / book | 3.6x
45th
|
3.6x
44th
|
3.8x
49th
|
| Price / tangible book | 3.9x
33rd
|
3.9x
35th
|
— |
| Price / free cash flow | 11.9x
17th
|
20.9x
49th
|
26.2x
56th
|
| Price / operating cash flow | 11.6x
17th
|
13.6x
32nd
|
25.6x
59th
|
| Enterprise value | $18.4B
93rd
|
$20.2B
93rd
|
$26.5B
96th
|
| EV / sales | 3.2x
22nd
|
6.4x
44th
|
6.4x
45th
|
| EV / EBITDA | 8.9x
22nd
|
12.1x
36th
|
21.7x
62nd
|
| EV / EBIT | 9.4x
22nd
|
12.7x
32nd
|
22.6x
52nd
|
| EV / free cash flow | 9.6x
12th
|
18.5x
39th
|
30.6x
61st
|
| Earnings yield | 7.0%
90th
|
5.7%
88th
|
3.5%
83rd
|
| FCF yield | 8.4%
95th
|
4.8%
85th
|
3.8%
83rd
|
| Operating cash flow yield | 8.6%
95th
|
7.4%
90th
|
3.9%
82nd
|
| Graham number (per share) | $72.86
72nd
|
$299.99
94th
|
$16.65
47th
|
Profitability (TTM)
12 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Gross margin | 92.6%
65th
|
86.1%
49th
|
39.9%
10th
|
| EBITDA margin | 35.5%
88th
|
53.1%
95th
|
29.5%
85th
|
| Operating margin | 31.8%
87th
|
44.5%
94th
|
32.3%
88th
|
| EBIT margin | 33.8%
89th
|
50.2%
96th
|
28.5%
86th
|
| Net margin | 27.7%
85th
|
41.6%
92nd
|
19.1%
81st
|
| NOPAT margin | 26.0%
85th
|
37.1%
93rd
|
28.1%
86th
|
| FCF margin | 33.0%
89th
|
34.6%
91st
|
21.0%
82nd
|
| Operating cash flow margin | 34.0%
89th
|
53.4%
96th
|
21.6%
80th
|
| R&D / revenue | 37.0%
41st
|
17.5%
20th
|
43.1%
48th
|
| SG&A / revenue | 24.0%
11th
|
23.2%
10th
|
17.6%
5th
|
| Stock comp / revenue | 3.2%
9th
|
4.9%
15th
|
1.7%
2nd
|
| Effective tax rate | 18.0%
18th
|
16.7%
16th
|
13.0%
11th
|
Returns on capital
11 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| ROE (on average equity) | 30.7%
88th
|
19.3%
80th
|
4.0%
74th
|
| ROA | 23.5%
90th
|
17.3%
87th
|
2.9%
76th
|
| ROIC | 82.1%
83rd
|
31.3%
63rd
|
11.9%
56th
|
| ROCE | 30.0%
95th
|
24.0%
88th
|
10.3%
79th
|
| Return on tangible assets | 28.8%
94th
|
21.0%
88th
|
4.4%
75th
|
| Cash ROIC (OCF / invested capital) | 107.2%
97th
|
45.1%
84th
|
9.2%
64th
|
| Gross profitability (GP / assets) | 68.5%
89th
|
37.6%
64th
|
30.7%
53rd
|
| ROIC, 3-yr average | — | 25.8%
88th
|
13.5%
80th
|
| ROIC, 5-yr average | -56.2%
29th
|
27.4%
71st
|
15.7%
67th
|
| ROE, 5-yr average | 16.1%
93rd
|
17.5%
94th
|
15.6%
92nd
|
| Incremental ROIC | 37.0%
62nd
|
-17.3%
29th
|
22.8%
54th
|
Growth
17 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Revenue growth (TTM YoY) | 26.9%
57th
|
2.5%
35th
|
-77.7%
6th
|
| Revenue growth (QoQ) | 31.5%
72nd
|
0.2%
24th
|
28.4%
70th
|
| Revenue CAGR, 3 yr | 18.3%
41st
|
14.3%
37th
|
-36.6%
8th
|
| Revenue CAGR, 5 yr | 16.4%
48th
|
14.7%
42nd
|
-10.8%
13th
|
| Gross profit CAGR, 3 yr | 18.7%
49th
|
12.6%
42nd
|
-38.1%
5th
|
| Operating income CAGR, 3 yr | 61.0%
82nd
|
8.8%
35th
|
-40.7%
0th
|
| Net income growth (TTM YoY) | 85.1%
61st
|
5.5%
35th
|
-89.4%
0th
|
| Net income CAGR, 3 yr | 63.9%
85th
|
14.6%
46th
|
-44.6%
0th
|
| EPS growth (TTM YoY) | 76.7%
61st
|
11.3%
35th
|
-89.4%
0th
|
| EPS CAGR, 3 yr | 68.3%
85th
|
17.6%
54th
|
-43.4%
0th
|
| EPS CAGR, 5 yr | 38.5%
80th
|
23.5%
67th
|
-19.6%
7th
|
| FCF growth (TTM YoY) | 103.1%
75th
|
2.1%
29th
|
-80.1%
0th
|
| FCF CAGR, 3 yr | 40.1%
62nd
|
17.5%
44th
|
-46.4%
0th
|
| Operating cash flow CAGR, 3 yr | 36.4%
75th
|
24.8%
50th
|
-47.2%
0th
|
| Book value CAGR, 3 yr | 13.2%
72nd
|
8.5%
65th
|
-39.5%
14th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 30.7%
57th
|
19.3%
31st
|
4.0%
11th
|
Margin history & stability
7 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Gross margin, 3-yr average | 91.8%
74th
|
88.0%
62nd
|
95.1%
81st
|
| Operating margin, 3-yr average | 18.1%
87th
|
46.6%
99th
|
34.3%
98th
|
| Net margin, 3-yr average | 16.4%
85th
|
40.9%
97th
|
29.4%
92nd
|
| FCF margin, 3-yr average | 16.7%
85th
|
34.3%
97th
|
27.1%
91st
|
| Revenue stability (0-1) | 0.92
81st
|
0.97
92nd
|
0.00
0th
|
| Earnings stability (0-1) | 0.32
42nd
|
0.98
98th
|
0.00
0th
|
| Margin stability (0-1) | 0.99
94th
|
0.97
82nd
|
0.97
78th
|
Liquidity (latest quarter)
7 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Cash & short-term investments | $4.5B
96th
|
$2.7B
94th
|
$1.5B
90th
|
| Net cash (− = net debt) | $4.5B
98th
|
$2.7B
95th
|
−$3.8B
0th
|
| Working capital | $4.8B
97th
|
$2.9B
94th
|
$1.7B
89th
|
| Current ratio | 4.66
43rd
|
5.73
57th
|
2.46
13th
|
| Quick ratio | 4.58
45th
|
5.41
56th
|
2.44
16th
|
| Cash ratio (cash + ST investments / current liabilities) | 3.46
44th
|
4.38
52nd
|
1.32
11th
|
| Defensive interval (days) | 584 days
61st
|
825 days
75th
|
405 days
34th
|
Leverage & solvency (latest quarter)
13 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Total debt | $38.3M
30th
|
$0
0th
|
$5.3B
100th
|
| Debt / equity | 0.01
7th
|
0.00
0th
|
0.89
79th
|
| Net debt / equity | −0.71
47th
|
−0.42
68th
|
0.63
93rd
|
| Debt / assets | 0.5%
6th
|
0.0%
0th
|
42.1%
82nd
|
| Debt / capital | 0.6%
7th
|
0.0%
0th
|
47.0%
79th
|
| Debt / EBITDA | 0.02
2nd
|
0.00
0th
|
4.32
81st
|
| Net debt / EBITDA | −2.17
30th
|
−1.59
46th
|
3.09
89th
|
| Interest coverage (EBIT / interest) | 847.5x
99th
|
132.1x
94th
|
4.4x
74th
|
| Cash interest coverage | 851.9x
99th
|
140.4x
95th
|
3.3x
71st
|
| Debt payback (years of OCF) | 0.0 yrs
2nd
|
0.0 yrs
0th
|
5.9 yrs
85th
|
| Liabilities / assets | 19.4%
29th
|
11.4%
15th
|
52.4%
65th
|
| IS credit model rating | AAA | AA | BBB+ |
| Implied credit spread (bps) | 50
0th
|
80
15th
|
225
46th
|
Efficiency
11 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Asset turnover | 0.85
86th
|
0.42
60th
|
0.15
34th
|
| Fixed asset turnover | 7.92
60th
|
1.63
28th
|
16.26
72nd
|
| Inventory turnover | 4.4
75th
|
2.4
50th
|
5.7
82nd
|
| Receivables turnover | 5.9
50th
|
9.1
71st
|
1.1
5th
|
| Days sales outstanding | 62 days
53rd
|
40 days
33rd
|
333 days
96th
|
| Days inventory outstanding | 83 days
25th
|
152 days
50th
|
64 days
18th
|
| Days payables outstanding | 209 days
55th
|
388 days
64th
|
0 days
0th
|
| Cash conversion cycle (days) | −64 days
35th
|
−197 days
25th
|
397 days
89th
|
| Capex / revenue | 1.0%
40th
|
18.8%
92nd
|
0.6%
25th
|
| Capex / depreciation | 0.60
64th
|
6.47
98th
|
0.52
59th
|
| Operating expense ratio | 52.0%
15th
|
45.1%
11th
|
57.5%
21st
|
Cash flow & earnings quality
7 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Operating cash flow / net income | 1.23
51st
|
1.29
57th
|
1.13
49th
|
| FCF / net income | 1.19
54th
|
0.83
43rd
|
1.10
51st
|
| FCF / operating cash flow | 97.0%
51st
|
64.9%
5th
|
97.4%
56th
|
| Capex / operating cash flow | 3.0%
49th
|
35.1%
95th
|
2.6%
44th
|
| Accruals ratio | -5.4%
51st
|
-4.9%
54th
|
-0.4%
71st
|
| Sloan accruals ratio | 34.2%
80th
|
-6.8%
25th
|
-71.7%
1st
|
| Earnings quality score (0-1) | 0.75
38th
|
1.00
81st
|
1.00
81st
|
Scores & forensic checks
15 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| IS score | 91
100th
|
73
90th
|
40
53rd
|
| IS profitability | 100
96th
|
93
90th
|
66
81st
|
| IS growth | 79
74th
|
46
27th
|
0
0th
|
| IS value | 67
93rd
|
55
90th
|
54
88th
|
| IS momentum | 99
95th
|
75
68th
|
36
18th
|
| IS risk (safety) | 100
52nd
|
100
52nd
|
65
40th
|
| IS quality | 97
100th
|
91
97th
|
70
82nd
|
| IS balance sheet | 96
97th
|
95
94th
|
56
41st
|
| IS earnings quality | 69
86th
|
80
99th
|
71
90th
|
| IS cash flow | 96
97th
|
79
90th
|
52
76th
|
| Piotroski F-score (0-9) | 8
97th
|
6
77th
|
4
33rd
|
| Altman Z-score | 11.8
80th
|
21.6
90th
|
2.8
43rd
|
| Beneish M-score | −2.45
46th
|
−3.01
28th
|
−3.51
16th
|
| Ohlson O-score | −13.29
4th
|
−14.64
1st
|
−7.76
30th
|
| IS credit score | 97
96th
|
89
82nd
|
64
49th
|
Size (TTM)
8 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| Market cap | $22.9B
95th
|
$22.9B
94th
|
$22.8B
93rd
|
| Revenue | $5.8B
97th
|
$3.2B
93rd
|
$4.1B
95th
|
| EBITDA | $2.1B
97th
|
$1.7B
96th
|
$1.2B
95th
|
| Net income | $1.6B
98th
|
$1.3B
97th
|
$788.1M
94th
|
| Free cash flow | $1.9B
99th
|
$1.1B
95th
|
$867.3M
93rd
|
| Total assets | $7.9B
94th
|
$7.2B
93rd
|
$12.5B
99th
|
| Shareholders' equity | $6.3B
96th
|
$6.4B
97th
|
$6.0B
95th
|
| Employees | 2,844
93rd
|
1,400
87th
|
3,119
95th
|
Price performance
9 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| 1 day | −0.2% | −1.6% | −2.2% |
| 1 week | +0.2% | −2.9% | −0.2% |
| 1 month | −11.4% | +7.2% | +7.2% |
| 3 months | −2.2% | +0.7% | +32.6% |
| 6 months | +15.6% | −9.4% | +29.6% |
| Year to date | +11.5% | +7.3% | +16.3% |
| 1 year | +28.3% | +23.4% | +13.1% |
| 3 years, cumulative | +98.5% | +127.3% | +4.9% |
| 5 years, cumulative | +71.6% | +172.9% | −13.8% |
Technicals
4 measures| Measure | INCY | UTHR | GMAB |
|---|---|---|---|
| RSI 14 | 39.4 | 53.1 | 57.5 |
| From 52-week high | −14.7% | −12.5% | −7.9% |
| From 52-week low | +34.6% | +30.3% | +56.6% |
| Beta | 0.74 | 0.56 | 0.65 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17